Neuren receives feedback on IND for Phelan-McDermid syndrome
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- US patent to 2034 granted for Neurens NNZ-2591 in autism
- $3.3 million raised from oversubscribed SPP
- Feedback on Angelman IND and submission of Pitt Hopkins IND
- IND application submitted for NNZ-2591 in Phelan-McDermid
- Share Purchase Plan Offer Booklet
Later from Neuren Pharmaceuticals
- Q3 2021 quarterly activity and cash flow report
- Neuren presenting at Bell Potter Healthcare Conference
- Positive topline results from Phase 3 trial in Rett syndrome
- Q4 2021 quarterly activity and cash flow report
- Notification regarding unquoted securities - NEU
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals